National Research Corp

Análisis de la acción National Research Corp (NRC)

$20.690

+0.221 (+1.07%)Al cierre

Loading chart…
Máximo
21.070
Apertura
20.470
Precio medio ponderado por volumen
20.73
Volumen
74.69K
Capitalización
548.94M
Mínimo
20.425
Importe
1.55M
EV/EBITDA, TTM
65.13

NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.

nrchealth.com

Análisis de IA of National Research Corp (NRC)

Mantener

Currently, NRC is not a strong buy due to its recent price decline and mixed financial performance. The current price is $20.15, with an RSI of 42.58 indicating it is nearing oversold territory. The forward P/E ratio is 17.21, suggesting reasonable valuation compared to its growth potential. However, the recent 5-day change is -0.89% and the 20-day change is -1.99%, indicating a downward trend. The main risk is the negative net income reported in Q2 2026, which was -$328,300, highlighting potential profitability issues. While the company has a solid long-term growth outlook, short-term volatility may warrant a hold position for now.

Métricas de valoración

El PER previsto actual de National Research Corp (NRC) es 17.21, frente a su media de 5 años de 26.12.

PER previsto

Valor razonable
Media 5A P/E
26.12
P/E actual
17.21
Sobrevalorada
36.16
Infravalorada
16.07

EV/EBITDA previsto

Muy sobrevalorado
Media 5A EV/EBITDA
19.52
EV/EBITDA actual
65.13
Sobrevalorada
33.89
Infravalorada
5.15

Precio/ventas previsto

Infravalorado
Media 5A P/S
5.76
P/S actual
2.93
Sobrevalorada
8.13
Infravalorada
3.39

Cronología de eventos

2026-08-12 (ET)

16:30:00

Resideo Appoints Shane Harrison as CFO

2026-05-19 (ET)

09:20:00

NRC Health Introduces New AI Features to Enhance Healthcare Interactions

2026-04-07 (ET)

09:20:00

NRC Health Expands Partnership with Ann & Robert H. Lurie Children's Hospital

2026-03-09 (ET)

16:40:00

NRC Health Authorizes Stock Repurchase Program Up to $60M

2026-03-04 (ET)

16:30:00

National Research Corporation TRCV Surpasses $152 Million

Noticias

Preguntas frecuentes sobre NRC, respondidas por Alphio AI

NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. It operates in the Industrials sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Currently, NRC is not a strong buy due to its recent price decline and mixed financial performance. The current price is $20.15, with an RSI of 42.58 indicating it is nearing oversold territory. The forward P/E ratio is 17.21, suggesting reasonable valuation compared to its growth potential. However, the recent 5-day change is -0.89% and the 20-day change is -1.99%, indicating a downward trend. The main risk is the negative net income reported in Q2 2026, which was -$328,300, highlighting potential profitability issues. While the company has a solid long-term growth outlook, short-term volatility may warrant a hold position for now.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar